<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003909</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01845</org_study_id>
    <secondary_id>COG-A09712</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000067087</secondary_id>
    <nct_id>NCT00003909</nct_id>
  </id_info>
  <brief_title>Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma</brief_title>
  <official_title>A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as motexafin&#xD;
      gadolinium may make the tumor cells more sensitive to radiation therapy. Phase I trial to&#xD;
      study the effectiveness of motexafin gadolinium plus radiation therapy in treating children&#xD;
      who have newly diagnosed brain stem glioma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) and schedule of motexafin gadolinium&#xD;
      administered prior to radiotherapy in children with newly diagnosed diffuse intrinsic pontine&#xD;
      glioma.&#xD;
&#xD;
      II. Determine the toxic effects of this drug given at the MTD in these patients.&#xD;
&#xD;
      III. Determine the intratumor and brain distribution of this drug by magnetic resonance&#xD;
      imaging (MRI) in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of motexafin gadolinium.&#xD;
&#xD;
      Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5&#xD;
      minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of motexafin gadolinium until the MTD is&#xD;
      determined. The first cohort receives motexafin gadolinium 5 days a week for 3 weeks; the&#xD;
      second cohort receives motexafin gadolinium 3 days a week for 6 weeks; and subsequent cohorts&#xD;
      receive motexafin gadolinium 5 days a week for 6 weeks. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using CTC version 2.0</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Untreated Childhood Brain Stem Glioma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>gadolinium texaphyrin</other_name>
    <other_name>Gd (III) Texaphryin</other_name>
    <other_name>Gd-Tex</other_name>
    <other_name>PCI-0120</other_name>
    <other_name>Xcytrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlatives studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically and radiographically (MRI) proven newly diagnosed diffuse intrinsic&#xD;
             brainstem glioma&#xD;
&#xD;
               -  Greater than 50% intra-axial involvement of the pons, pons and medulla, pons and&#xD;
                  midbrain, or entire brainstem&#xD;
&#xD;
               -  Contiguous involvement of the thalamus or upper cervical cord allowed&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No glucose 6 phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGOT or SGPT less than 1.5 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent corticosteroid therapy allowed for increased intracranial pressure only&#xD;
&#xD;
          -  No prior cranial radiotherapy&#xD;
&#xD;
          -  No prior motexafin gadolinium&#xD;
&#xD;
          -  No other concurrent experimental agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minesh Mehta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

